Implementation of the Fatty Liver Index in Primary Care

Launched by CONSORCI SANITARI DE L'ALT PENEDÈS I GARRAF · Apr 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a simple screening test called the Fatty Liver Index can help doctors identify and manage heart health risks in people at risk for liver issues, specifically hepatic steatosis (a condition where fat builds up in the liver). The trial involves two groups of medical teams in a primary care setting: one group will use the Fatty Liver Index in their practice, while the other will not. Researchers will compare how many patients in each group receive interventions to control their cardiovascular risk, such as lifestyle changes or medications.

To participate in the trial, individuals must be 14 years or older, have a body mass index (BMI) of 25 or more (indicating they are overweight), and be willing to follow up at the study center. Unfortunately, pregnant women, people with certain liver diseases, those who consume alcohol above a specific limit, and patients with complex health issues won't be eligible. Participants can expect regular health check-ups, support in managing their weight and cardiovascular health, and the chance to contribute to important research that could improve care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women aged 14 years and older.
• • Attended at the Basic Care Units (BCU) participating in the Primary Care Center Baix a Mar study.
• • Intention to undergo medical follow-up at the study center.
• • Body mass index ≥ 25.
• Exclusion Criteria:
• • Pregnant women
• • Alcohol consumption habit (Standard Drink Unit (SDU); one SDU equals 10 grams of alcohol. Risky consumption is considered from 4 SDUs in men and 2 SDUs in women).
• • Displaced patients not assigned to the study center.
• • Patients classified as Advanced Chronic Care Model or Complex Chronic Patient.
• • Participants diagnosed with any of the following pathologies: Chronic liver diseases, including hepatic steatosis; Dementia; Active oncological diseases
• • Cognitive or affective pathology that limits the ability to collaborate with lifestyle interventions carried out at the center.
• • Patients under the care of endocrinology specialists.
• • Participation in another clinical trial involving an experimental intervention during the period of this trial.